Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma (CARMEN)

Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma

This is a multicenter,open-label trial to evaluate activity and safety of the investigational intensive in HIV+ patients with Burkitt's lymphoma.

Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.

Until recently, the immuno-compromised state of patients with concomitant HIV/AIDS and BL was thought to limit the ability to administer intensive chemotherapeutic regimens due to infection rate. However, the advent of highly active antiretroviral therapy (HAART) and evidence in diffuse large B-cell lymphomas that HIV-positive patients can tolerate standard chemotherapeutic regimens with improved outcomes have led investigators to treat HIV-positive patients with the same intensive chemotherapy regimens used to treat immuno-competent patients. Data suggest that these current approaches, along with supportive care, may result in improved patient outcomes, similar to those in the immuno-competent patient population.

Study Overview

• Status: Completed
• Conditions: HIV; Burkitt's Lymphoma
• Intervention / Treatment: Drug: Induction Phase; Drug: Consolidation Phase (on day +50); Drug: Intensification phase; Drug: BEAM conditioning; Radiation: Consolidation radiotherapy

Detailed Description

The activity of feasibility of the proposed program will be assessed in HIV+ patients with Burkitt lymphoma with the aim to improve tolerability, minimize source consuming and supporting treatment and redu ce late sequels. Available combinations in this setting are really source demanding and toxic combinations showing high rates of septic complication and a treatment-related mortality of near 20%.

• Study Type: Interventional
• Enrollment (Actual): 19
• Phase: Phase 2

Contacts and Locations

Study Locations

• Italy
  • Aviano (PN), Italy
    • Oncologia Medica A - Centro di Riferimento Oncologico
  • Brescia, Italy
    • Ematologia - A.O. Spedali Civili
  • Milano, Italy
    • Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor
  • Milano, Italy
    • S.C. Oncologia Medica - Ospedale San Paolo
  • Milano, Italy
    • S.C. Oncologia Medica 3 - IRCCS Istituto Nazionale Tumori (INT)
  • Roma, Italy
    • U.O.C. Immunodeficienze virali - I.N.M.I. L. Spallanzani
  • Terni, Italy
    • S.C. Oncoematologia - A.O. Santa Maria
  • Torino, Italy
    • U.O. Ematologia 2 - Ospedale San Giovanni Battista

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologic diagnosis of Burkitt's lymphoma (WHO 2008)
• HIV sero-positivity
• Age ≥18 and ≤60 years
• ECOG-PS ≤3

Exclusion Criteria:

• CNS parenchymal involvement
• Absolute neutrophil count <1.000 cells/μL and platelets count <75 × 109/L (Burkitt unrelated)
• Creatinine >1,5N (Burkitt unrelated)
• SGOT and/or SGTP >2,5N (Burkitt unrelated)
• Bilirubin >2N (Burkitt unrelated)
• Severe psychiatric illness or any other clinical, social or psychological condition that could interfere with patient's adherence and compliance
• Significant cardiac disease or acute myocardial infarction in the last 12 months
• Severe active infection (except for HBV and/or HCV co-infection)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: intensive short term immuno-chemotherapy; Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.

Drug: Induction Phase; dd -2 to 1: Methylprednisolone; dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine; dd 2, Rituximab; dd 7, Methotrexate; dd 14, Rituximab; dd 15, Etoposide; dd 21, Methotrexate; dd 29, Rituximab and Doxorubicin; dd 36, Rituximab and VCR At the end of this induction phase, subsequent treatment will be performed according to the objective response: pts in CR: consolidation phase followed by bulky site irradiation; pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation; pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation; Other Names: Short-term intensive sequential chemoimmunotherapy; Drug: Consolidation Phase (on day +50); dd 1-2: cytarabine twice a day; dd 3 and 11: rituximab; dd 11-13: leukapheresis for PBPC collection.; Other Names: high-dose cytarabine; consolidation phase; Drug: Intensification phase; One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.; CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);; AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed).; Other Names: unresponsive patients, refractory disease; Drug: BEAM conditioning; BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells; Other Names: Conditioning regimen, autologous transplantation; Radiation: Consolidation radiotherapy; At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy; Other Names: bulky irradiation; residual lesion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
evaluation of activity of the induction phase in terms of complete remission rate	Objective lymphoma response achieved after the induction phase of the experimental treatment.	at the end of the induction phase of the investigational intensive chemotherapy, an expected average of 45 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility and tolerability of the investigational intensive chemotherapy in terms of grade ≥4 adverse events	Assessment of incidence of grade 4 AE during experimental treatment (induction, consolidation and intensification phases as well as conditioning and autologous stem cell transplantation (if indicated)	participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Feasibility and tolerability of the consolidation phase followed by BEAM conditioning and autologous stem cell transplantation in terms of prevalence of grade ≥4 adverse events		participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Feasibility and tolerability of intensification phase in terms of prevalence of grade ≥4 adverse events	Participants who will not achieve a complete or partial response after induction and consolidation phases will be referred to intensification phase, which will be followed by BEAM + ASCT. These patients will be assess for tolerabbility and AE during these therapeutic phases.	participants will be followed for the duration of the whole experimental program, an expected average of 100 days
Activity of the whole investigational program in terms of complete remission rate	Participants will be assessed by conventional exams to define complete remission rate after the whole experiemntal program; that is after consolidation phase for patients who achieved complete remission after induction phase, after BEAM + ASCt for patients who achieved partial response after induction phase, and after intensification phase for patients who did not achieve an objective response after induction phase.	at the end of the whole program, an expected average of 100 days

Collaborators and Investigators

• Sponsor: Andres J. M. Ferreri
• Investigators: Study Chair: Andrés JM Ferreri, MD, San Raffaele Scientific Institute, Milano, Italy

Study record dates

Study Major Dates

• Study Start: November 1, 2011
• Primary Completion (Actual): April 1, 2013
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: January 6, 2012
• First Submitted That Met QC Criteria: January 24, 2012
• First Posted (Estimate): January 25, 2012

Study Record Updates

• Last Update Posted (Actual): August 4, 2022
• Last Update Submitted That Met QC Criteria: August 2, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: HIV; Burkitt's lymphoma; intensive; short term; immuno-chemotherapy; HIV-positive patients with Burkitt's lymphoma
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; DNA Virus Infections; Tumor Virus Infections; Epstein-Barr Virus Infections; Herpesviridae Infections; HIV Infections; Lymphoma, B-Cell; Lymphoma; Burkitt Lymphoma; HIV Seropositivity; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Cytarabine
• Other Study ID Numbers: CARMEN